| | Business Summary | | Northfield
Laboratories
Inc.
is
engaged
in
the
development
of
a
safe
and
effective
alternative
to
transfused
blood
for
use
in
the
treatment
of
acute
blood
loss.
Its
PolyHeme
blood
substitute
product
is
a
solution
of
chemically
modified
hemoglobin
derived
from
human
blood.
Clinical
studies,
to
date,
indicate
that
PolyHeme
carries
as
much
oxygen,
and
loads
and
unloads
oxygen
in
the
same
manner,
as
transfused
blood.
Clinical
studies
also
indicate
that
PolyHeme
is
universally
compatible,
and,
accordingly,
should
not
require
blood
typing
prior
to
infusion.
Therefore,
PolyHeme
should
be
available
for
immediate
use
in
emergency
situations.
In
addition,
PolyHeme
has
an
extended
shelf
life
compared
to
blood. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Northfield
Laboratories,
a
development
stage
company,
is
engaged
in
the
research,
development,
manufacturing,
testing
marketing
and
distribution
of
a
hemoglobin-based
blood
substitute
product.
For
the
fiscal
year
ended
5/31/01,
the
Company
reported
no
revenues.
Net
loss
rose
11%
to
$10.2
million.
Higher
loss
reflects
increased
general
and
administrative
expenses
due
to
higher
professional
fees,
and
lower
interest
income
due
to
lower
available
investment
balances. | | More
from
Market Guide: Significant
Developments |
| | | | FY2001 Pay | |
| Richard DeWoskin, 53
Chairman,
CEO | $295K | Steven Gould, M.D., 54
Pres | 313K | Jack Kogut, 54
VP-
Fin., Sec. and Treasurer | 250K | Marc Doubleday, 42
VP-
Process Engineering | 178K | John Dybas, Jr., 63
VP-
Regulatory Affairs | 189K | | Dollar amounts are as of 31-May-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/n/nfld.gif)